August 7th 2023
The resubmitted biologics license application for remestemcel-L has been issued a complete response letter.
2nd Annual International Congress on Pediatric Oncology
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
Clinical Vignettes: Inaugural International Congress on Pediatric Oncology
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
A Focus on Acute Myeloid Leukemia
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
25th Annual International Lung Cancer Congress®
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More
Community Practice Connections™: Multidisciplinary Strategies for Improving Outcomes in CML from Frontline Care… and Beyond!
View More
7th Annual School of Nursing Oncology™
View More
Myeloma Management Considerations: Applying the Evidence With Monoclonal Antibody Based Regimens
View More
Challenges Faced by Adolescent and Young Adult Patients With Cancer
Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.
FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease
August 26th 2022Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.
Early Trial Suggests that Targeting CLL1-Postive Cells is Effective in Treating Pediatric AML
June 26th 2021An early trial evaluated Anti-C-type lectin-like molecule-1 (CLL-1)-based CAR T cells for its safety and efficacy in improving the symptoms of pediatric patients with acute myeloid leukemia (AML).
FDA Approves Radiopharmaceutical Diagnostic Agent for Pediatric Patients
June 10th 2021The FDA approved injectable technetium Tc 99m tilmanocept (Lymphoseek), a radiopharmaceutical agent that targets lymphatic mapping and guiding for sentinel lymph node biopsies (SLNB), for use in pediatric patients with melanoma, rhabdomyosarcoma, and other solid tumors.
Age Associated With Survival, Time to Richter Transformation in AYA Patients With CLL
May 30th 2021Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.